Streetbeat News

Products Services

NXTC

NextCure, Inc. (NASDAQ:NXTC) has presented preclinical data on NC181, a novel therapeutic candidate targeting ApoE4, for the treatment of Alzheimer's disease. The data, presented at the 2nd Annual Neurodegeneration Targets Conference, showed that NC181 demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance, and other important findings in preclinical testing. Further studies to characterize NC181 as a potential therapeutic for Alzheimer's disease and Cerebral Amyloid Angiopathy (CAA) are ongoing.

Portfolio Pulse from Happy Mohamed

September 26, 2023 | 8:12 pm

GILD

Gilead Sciences has announced the discontinuation of its Magrolimab study in Acute Myeloid Leukemia (AML) with TP53 mutations. The decision was based on an ad hoc analysis and an independent data monitoring committee review, which concluded that Magrolimab is unlikely to demonstrate a survival benefit.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:10 pm

CRDF

Cardiff Oncology, Inc. (NASDAQ:CRDF) has announced positive clinical data from its ongoing trials of onvansertib monotherapy and combination therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC). The company also plans to initiate a first-line trial for mPDAC. The data from the trials show promising results, with the pancreatic cancer Phase 2 trial showing greater efficacy compared to historical controls. The company will hold a conference call to discuss the preliminary data.

Portfolio Pulse from Happy Mohamed

September 26, 2023 | 8:09 pm

ADVM

Adverum Biotechnologies has reported Aflibercept protein level data from its LUNA Phase 2 trial. The company states that Ixo-vec has been well tolerated with a favorable preliminary safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:07 pm

GRCL

Gracell Biotechnologies has dosed the first patient in a Phase 1b/2 clinical trial in the U.S. for its lead candidate, GC012F, for the treatment of relapsed or refractory multiple myeloma (RRMM). The trial will evaluate the safety, tolerability, and efficacy of GC012F, which is developed on the proprietary FasTCAR next-day manufacturing platform. GC012F has shown promising results in prior clinical studies, with a 93.1% overall response rate among high-risk RRMM patients.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:01 pm

IONS

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shares rose after the company announced that the Phase 3 Balance study of olezarsen met the primary endpoint with a significant reduction in triglyceride levels. The company plans to file a New Drug Application with the FDA. The positive results boosted Ionis stock.

Portfolio Pulse from Ryan Gustafson

September 26, 2023 | 7:49 pm

CYBN

Cybin Inc. (NYSE:CYBN) and psychedelic therapy education organization Fluence have partnered to streamline and scale Cybin's EMBARK facilitator training program for a global Phase 3 trial of deuterated psilocybin analog CYB003 for major depressive disorder treatment. Fluence will assist Cybin in selecting and training facilitators for the trial, produce additional video content, and offer both real-time and self-paced training.

Portfolio Pulse from Lara Goldstein

September 26, 2023 | 7:40 pm

SLNO

Soleno Therapeutics Inc (NASDAQ:SLNO) released positive top-line results from a long-term treatment study of DCCR for Prader-Willi syndrome (PWS). Cantor Fitzgerald raised the price target on Soleno Therapeutics from $19 to $35, with an Overweight rating. The analysts believe the PWS market could hold significant appeal for Soleno Therapeutics and that the stock remains undervalued.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 7:18 pm

SONY

Sony Group Corp is offering a free PS5 digital game to new PlayStation 5 owners in the U.S. who purchase and activate their console between Sept. 20 and Oct. 20, 2023. The offer includes popular titles such as Marvel's Spider-Man: Miles Morales, God of War: Ragnarok, and more. The company aims to sell 25 million PS5s this financial year, a record for PlayStation consoles.

Portfolio Pulse from Franca Quarneti

September 26, 2023 | 7:16 pm

PLRX

Pliant Therapeutics Inc (NASDAQ:PLRX) announced positive data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints, demonstrating that bexotegrast was well tolerated and its plasma concentrations increased with dose. The trial's exploratory efficacy endpoints showed bexotegrast reduced both ELF scores and PRO-C3 levels at Week 12 at all doses relative to placebo. PLRX shares were up 13.10% at $16.48 on the last check Tuesday.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 6:56 pm